Sequana/Sloan-Kettering genomic research venture will focus on prostate, breast and colon cancer.
SEQUANA/SLOAN-KETTERING VENTURE TO FOCUS ON PROSTATE, BREAST, COLON CANCER genomic research, Sequana announced Aug. 20. The focus of the research will be on "cancers caused by `somatic' mutations -- non-hereditary defects occurring in the genes of the body's cells that increase the risk for developing cancer," Sequana explained. Research will be aimed at identifying gene defects in the early stages of cancer and relating the gene defects to the subsequent course of treatment. The researchers will be looking to "provide tests that could predict how tumors will progress and respond to different therapies."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth